Saniona AB (SANION) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Saniona AB (SANION) has a cash flow conversion efficiency ratio of -0.125x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-79.51 Million ≈ $-8.56 Million USD) by net assets (Skr635.16 Million ≈ $68.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SANION defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Saniona AB - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Saniona AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Saniona AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Saniona AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Excelliance MOS
TWO:5299
|
0.024x |
|
Aurona Industries
TWO:8074
|
0.050x |
|
WildBrain Ltd
TO:WILD
|
0.095x |
|
Yatra Online Limited
NSE:YATRA
|
0.110x |
|
Gulf Island Fabrication Inc
NASDAQ:GIFI
|
0.030x |
|
Onewater Marine
NASDAQ:ONEW
|
0.195x |
|
TON Strategy Co
NASDAQ:TONX
|
-0.015x |
|
SOL-GEL TECHN. IS-10
F:4SG
|
N/A |
Annual Cash Flow Conversion Efficiency for Saniona AB (2013–2025)
The table below shows the annual cash flow conversion efficiency of Saniona AB from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Saniona AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr635.16 Million ≈ $68.35 Million |
Skr273.86 Million ≈ $29.47 Million |
0.431x | -59.89% |
| 2024-12-31 | Skr231.82 Million ≈ $24.95 Million |
Skr249.20 Million ≈ $26.82 Million |
1.075x | -72.43% |
| 2023-12-31 | Skr-21.94 Million ≈ $-2.36 Million |
Skr-85.53 Million ≈ $-9.20 Million |
3.898x | +172.98% |
| 2022-12-31 | Skr52.71 Million ≈ $5.67 Million |
Skr-281.54 Million ≈ $-30.30 Million |
-5.341x | -336.56% |
| 2021-12-31 | Skr282.00 Million ≈ $30.35 Million |
Skr-345.04 Million ≈ $-37.13 Million |
-1.224x | -322.61% |
| 2020-12-31 | Skr603.46 Million ≈ $64.94 Million |
Skr-174.71 Million ≈ $-18.80 Million |
-0.290x | +82.82% |
| 2019-12-31 | Skr58.44 Million ≈ $6.29 Million |
Skr-98.47 Million ≈ $-10.60 Million |
-1.685x | -190.08% |
| 2018-12-31 | Skr39.46 Million ≈ $4.25 Million |
Skr-22.92 Million ≈ $-2.47 Million |
-0.581x | +61.88% |
| 2017-12-31 | Skr37.63 Million ≈ $4.05 Million |
Skr-57.34 Million ≈ $-6.17 Million |
-1.524x | -1139.50% |
| 2016-12-31 | Skr54.25 Million ≈ $5.84 Million |
Skr7.95 Million ≈ $855.87K |
0.147x | +126.93% |
| 2015-12-31 | Skr52.94 Million ≈ $5.70 Million |
Skr-28.82 Million ≈ $-3.10 Million |
-0.544x | +39.93% |
| 2014-12-31 | Skr8.78 Million ≈ $944.98K |
Skr-7.96 Million ≈ $-856.41K |
-0.906x | +86.10% |
| 2013-12-31 | Skr575.00K ≈ $61.88K |
Skr-3.75 Million ≈ $-403.34K |
-6.518x | -- |
About Saniona AB
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company's product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical t… Read more